PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PREDNISOLONE, THERAPEUTIC”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1994

Combined treatment of autoimmune MRL/MP-lpr/lpr mice with a herbal medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to) plus suboptimal dosage of prednisolone.

Therapeutic effects of combined treatment with a Chinese medicine prescription, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to, NYT) and suboptimal doses of prednisolone (PSL) on pathological findings of autoimmune-prone MRL/lpr mice were examined. Six-week-old MRL/lpr mice were treated orally with 1000 mg/kg of NYT, 0.5 or 2 mg/kg of PSL, 1000 mg/kg of NYT plus 0.5 or 2 mg/kg of PSL (combined treatment) or solvent only (control) six times per week. The rates of signs and symptoms of autoimmune disease (lymphadenopathy, proteinuria, dermatitis, loss of hair) were suppressed significantly in groups given PSL (2 mg/kg) alone, NYT alone and combined treatment with PSL (2 mg/kg) plus NYT (1000 mg/kg) compared with control, respectively, whereas treatment with PSL (0.5 mg/kg) alone did not inhibit their occurrence. ConA response and IL-2 production were also improved significantly in lymphocytes of mice given the combined treatment. Interestingly, treatment with NYT alone enhanced further the augmented IFN-gamma production in MRL/lpr mice but the combined treatment suppressed such an augmented production. The combined treatment dramatically reduced the level of anti-DNA antibodies in serum of MRL/lpr mice. By contrast, NYT alone treatment had no effect on autoantibodies production. These results suggest that combined treatment with NYT plus a suboptimal dose of PSL could be effective for systemic lupus erythematosus without severe side-effects.

Animals↗
PubMed1990

Prednisolone therapy of experimental allergic neuritis in Lewis rats does not induce relapsing or chronic disease.

The effects of therapeutic prednisolone treatment on experimental allergic neuritis (EAN) in Lewis rats were evaluated in a controlled clinical and electrophysiological study. Since steroid therapy has been suspected to cause relapsing or chronic disease, monitoring was extended over 200 days. Short-term steroid treatment (5 days of 15 mg/kg prednisolone, n = 8) with sudden steroid withdrawal was compared with long-term application (30 days, beginning at 7.5 mg/kg) in descending dosage (n = 8). The experiment included saline-injected controls (n = 8) and controls for stress possibly exerted by the handling of the animals. Treatment was begun at the onset of clinical signs. The clinical and electrophysiological data indicated that deterioration, recovery and mild (insignificant) relapse (after day 30 and day 108) occurred in all groups at the same time. Both steroid application schemes significantly (p less than 0.03) attenuated the severity and shortened the duration of EAN. Relapse was not aggravated after steroid treatment. The clinical course and electrophysiological findings were unaltered by the experimental procedures and by mild experimental stress.

Animals↗
PubMed1991

The bioavailability and therapeutic effectiveness of prednisolone acetate vs. prednisolone sodium phosphate: a 20-year review.

The superior bioavailability and therapeutic effect of prednisolone acetate over prednisolone sodium phosphate was described about 15 years ago. Review of the original articles and subsequent studies show that in clinical situations the two medications are probably equally effective. Further, patient compliance studies show that prednisolone sodium phosphate may actually be superior.

Animals↗
PubMed1992

An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use.

Prednisolone metasulphabenzoate, a steroid with poor colonic absorption, was coated with the pH-dependent acrylic resin Eudragit S, as a means of delivering an orally administered preparation to the proximal colon. The therapeutic potential of delivering this steroid with potentially less systemic side-effects to the proximal colon was assessed in extensive ulcerative colitis. Plasma and urine prednisolone profiles in 6 healthy volunteers confirmed minimal absorption from Eudragit S-coated prednisolone metasulphabenzoate compared to prednisolone acetate: peak plasma prednisolone concentrations 29 +/- 21 ng/ml vs. 570 +/- 185 ng/ml (P less than 0.01), area under curve measurements 204 +/- 214 vs. 2724 +/- 1236 ng.h/ml (P less than 0.01). Prednisolone metasulphabenzoate coated with Eudragit S (30-60 mg daily) was then administered for 12 weeks to 12 patients with colonoscopically proven extensive ulcerative colitis in relapse. Symptoms, sigmoidoscopic appearances and rectal histological abnormalities all improved during therapy. Complete clinical remission occurred in 7 patients, a partial response in 2 patients and no response in 3 patients. Cortisol responses to tetracosactrin demonstrated no significant adrenal suppression following treatment. Eudragit S-coated prednisolone metasulphabenzoate may be a useful treatment for extensive ulcerative colitis, without risk of systemic steroid side-effects.

Acrylic Resins↗
PubMed1994

[Therapeutic effectiveness of prednisolone in Mycoplasma pulmonis-infected pneumonia in mice].

The present investigation was designed to analyze the therapeutic efficacy of prednisolone in the development of pulmonary lesions in Mycoplasma pulmonis-infected mice. Mice were treated every day from day 3 to day 9 after M. pulmonis inoculation with minocycline (group M), prednisolone (group P), or with minocycline and prednisolone (group MP) and a control group was left untreated. Mice from each group were sacrificed at days 7, 14, and 21. The macroscopic lung lesion scores of group MP at days 7, 14, 21, and of group M at day 7 were significantly lower (p < 0.05) compared with the control group. Pathological findings in group M and MP showed reduction of the polymorphonuclear leukocyte response in the alveoli compared with the controls. However, infiltration of lymphocytes around the bronchioles and blood vessels of group M was not less than that in group MP. The titer of CF antibody in group MP was the lowest of the four groups. Among the four groups, M. pulmonis was cultured in the joints of group P. These results suggest that combination therapy with minocycline and prednisolone was effective because the mice of group MP had a more marked reduction of infiltration of lymphocytes around the bronchioles and blood vessels as compared with group M. Simultaneously, with prednisolone alone therapy, a risk of dissemination of the mycoplasma organism and diminution of antibody production were suggested.

Animals↗
PubMed1985

[Evaluation of therapeutic effectiveness of prednisolone in patients with chronic active hepatitis based on the morphometry of liver biopsy specimens].

In 42 patients with chronic active hepatitis (CAH), liver biopsies were subjected to histological study and morphometry before and after prednisolone treatment (21 patients comprising group I) and treatment with a complex of vitamins B1, B6, B12 and C (21 patients comprising group II). Combined study of liver biopsies during treatment makes it possible to evaluate objectively enough the results of prednisolone therapy of CAH patients. The authors confirmed the efficacy of prednisolone therapy of patients with sero-negative CAH. These patients demonstrated a reduction in dystrophic alterations, volume of inflammatory cells in the portal tracts and in the areas of necrosis, a lowering of the number of aggressive lymphocytes. Prednisolone was discovered to have an adverse effect on seropositive CAH, to activate virus replication in liver tissue, intensify necrotic alterations in the parenchyma and inflammatory reaction in the portal tracts.

Ascorbic Acid↗